CAPTRUST Financial Advisors
LYEL icon

CAPTRUST Financial Advisors’s Lyell Immunopharma LYEL Stock Holding History

CAPTRUST Financial Advisors’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-8
Closed -$1K – 3198
2022
Q2 		$1K Buy
+8
New +$817 ﹤0.01% 4693
2022
Q1 		– Sell
-39
Closed -$6K – 5045
2021
Q4 		$6K Buy
39
+37
+1,850% +$8.25K ﹤0.01% 3993
2021
Q3 		$1K Buy
+2
New +$599 ﹤0.01% 4446

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
A
Apoletto Road Town, Tortola, British Virgin Islands $260M AUM 31.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

CAPTRUST Financial Advisors's LYEL Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Lyell Immunopharma (LYEL) in Q3 2022, closing a stake of 8 shares — an estimated $1K sold.

CAPTRUST Financial Advisors first reported a position in LYEL in Q3 2021 and held it in 3 quarters. The position peaked at $6K in Q4 2021. 93 funds tracked by Wall St. Rank hold LYEL as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Lyell Immunopharma position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 8 Lyell Immunopharma shares in Q3 2022, an estimated $1K.
  • CAPTRUST Financial Advisors first reported a position in Lyell Immunopharma in Q3 2021 and held it in 3 quarters.
  • CAPTRUST Financial Advisors's Lyell Immunopharma position peaked at $6K in Q4 2021.
  • 93 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.